Nowrouzi-Sohrabi Peyman, Soroush Negin, Tabrizi Reza, Shabani-Borujeni Mojtaba, Rezaei Shahla, Jafari Fatemeh, Hosseini-Bensenjan Mahnaz, Stricker Bruno H, van Hoek Mandy, Ahmadizar Fariba
Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Front Pharmacol. 2021 Mar 29;12:618208. doi: 10.3389/fphar.2021.618208. eCollection 2021.
: Whether liraglutide use improves cardiometabolic risk factors in different subsets of subjects with coronary artery disease (CAD) remains unclear. In a systematic review and meta-analysis, we quantified the effects of liraglutide on cardiometabolic risk profile in subjects with CAD with or without type 2 diabetes mellitus (T2D). : Online database searches were conducted in PubMed, Scopus, EMBASE, Web of Science, Cochrane library, and Google Scholar from incept up to 15th January 2021. We identified randomized controlled trials (RCTs) assessing the effects of liraglutide compared to placebo on cardiometabolic risk profile. We used the random- or fixed-effect models to pool the weighted mean differences (WMDs) and 95% confidence intervals (CIs). : Out of a total of 7,320 citations, six articles (seven RCTs) with 294 subjects with CAD (mean age, 61.21 years; 19% women) were included. Our findings presented as WMD and 95% CI showed a statistical significant decrease in hemoglobin A1c (HbA1c) [-0.36%; -0.47; -0.26, < 0.001; = 0.0% (with 6 RCTs)], body mass index (BMI) [-0.61 kg/m; -1.21; -0.01, = 0.047; = 72.2% (with five RCTs)], and waist circumference [-2.41 cm; -3.47; -1.36, < 0.001; = 0.0% (with three RCTs)]. Through a set of subgroup analyses, we found a significant reduction in BMI in CAD patients with T2D [WMD = -1.06; 95% CI, -1.42, -0.70, < 0.001; = 0.0% (with three RCTs)] compared to CAD only patients [WMD = -0.08; 95% CI, -0.45, 0.29, = 0.66; = 0.0% (with two RCTs)] in the liraglutide group compared with the placebo group. No significant changes in heart rate, blood pressure, and lipid profiles were observed. : Among people with established CAD, liraglutide significantly improved HbA1c, BMI, and waist circumference values. The effect of liraglutide on BMI was more robust in individuals with T2D compared to those without.
利拉鲁肽的使用是否能改善不同亚组冠心病（CAD）患者的心脏代谢危险因素仍不清楚。在一项系统评价和荟萃分析中，我们量化了利拉鲁肽对合并或不合并2型糖尿病（T2D）的CAD患者心脏代谢风险状况的影响。在PubMed、Scopus、EMBASE、Web of Science、Cochrane图书馆和谷歌学术上进行了在线数据库检索，检索时间从建库至2021年1月15日。我们纳入了评估利拉鲁肽与安慰剂相比对心脏代谢风险状况影响的随机对照试验（RCT）。我们使用随机或固定效应模型汇总加权平均差（WMD）和95%置信区间（CI）。在总共7320条引用文献中，纳入了6篇文章（7项RCT），涉及294例CAD患者（平均年龄61.21岁；19%为女性）。我们以WMD和95%CI呈现的研究结果显示，糖化血红蛋白（HbA1c）[−0.36%；−0.47；−0.26，P<0.001；I² = 0.0%（6项RCT）]、体重指数（BMI）[−0.61kg/m²；−1.21；−0.01，P = 0.047；I² = 72.2%（5项RCT）]和腰围[−2.41cm；−3.47；−1.36，P<0.001；I² = 0.0%（3项RCT）]有统计学意义的显著降低。通过一系列亚组分析，我们发现与仅患有CAD的患者相比，利拉鲁肽组中合并T2D的CAD患者的BMI显著降低[WMD = −1.06；95%CI，−1.42，−0.70，P<0.001；I² = 0.0%（3项RCT）]，而仅患有CAD的患者[WMD = −0.08；95%CI，−0.45，0.29，P = 0.66；I² = 0.0%（2项RCT）]。未观察到心率、血压和血脂谱有显著变化。在已确诊CAD的人群中，利拉鲁肽显著改善了HbA1c、BMI和腰围值。与未患T2D的个体相比，利拉鲁肽对BMI的影响在T2D个体中更强。
